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Abstract
Introduction: Chemokine ligand 5, also known as CCL5 or regulated on activation
normal T-cell expressed and secreted (RANTES), is a chemokine expressed in
inflamed tissue and capable of inducing migration of immature dendritic cells
(DCs) or Langerhans cells. In this study, we explored the effect of RANTES on
EG7 cells. 
Material and methods: In vivo, RANTES gene transfer reduced the tumourigenic
capacity of EG7 and prolonged the survival of tumour-bearing mice. To reveal
the underlying mechanism, we performed the following experiments and
provided evidence to support our hypothesis of RANTES gene therapy for EG7.
Higher natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity was
induced after RANTES gene transfer, accompanied by higher levels of Th1 type
cytokines (IL-2 and IFN-γ). 
Results: Tumour necrosis was also markedly observed in the tumour tissues after
RANTES gene transfer, which was attributed to reduced expression of vascular
endothelial growth factor (VEGF) and matrix metalloproteinase (MMP-2). 
Conclusions: We draw the conclusion that reduced tumourigenicity of EG7 after
RANTES gene transfer can be attributed to higher NK cell and CTL activity, anti-
angiogenesis and higher levels of Th1 type cytokines induced by RANTES. These
results support the notion that higher chemokine expression in tumour tissue
elicits potent anti-tumour immunity. 
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Introduction
Cytokine gene transfer to cancer cells has been recently developed as
an attractive mechanism of drug delivery in situ without the toxic effects
associated with systemic administration.
Chemokines are small polypeptide signalling molecules that bind to
and activate a family of seven transmembrane G protein-coupled
chemokine receptors and are responsible for the selective recruitment
and activation of mononuclear cells [1]. Chemokine ligand 5, also known
as CCL5 or RANTES, is a protein which in humans is encoded by the
CCL5 gene [2]. CCL5 is an 8 kD protein classified as a chemotactic
cytokine or chemokine. Regulated on activation normal T-cell expressed
and secreted (RANTES) or CCL5 is a member of the consecutive cysteine
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(CC) chemokines that promotes the migration and
activation of several types of leukocytes, such as
CD4+/CD8+ T-cells, NK cells and DCs, expressing
CC-chemokine receptors (CCR1), CCR3 and CCR5
[1, 3-6]. Interestingly, it was reported recently that
RANTES plasmid had a potent efficiency for DC
recruitment and Th1 bias when it was co-injected
with HBV DNA vaccine [3]. Moreover, the vaccine,
comprised of an oncolytic adenovirus expressing
RANTES (Ad-RANTES-E1A) [7], enhanced tumour
infiltration and maturation of antigen-presenting
cells  in vivo. This vaccine recruited DCs,
macrophages, natural killer cells, and CD8+ T cells
to the tumour site, and thus enhanced antigen-
specific cytotoxic T lymphocyte responses and the
NK cell response. This in situ immunization
strategy could be a potent anti-tumour
immunotherapy approach for aggressive
established tumours. Consistent with the above
results [8], vaccination combination with Fit3L and
RANTES in a DNA prime-protein boost regimen
also elicits strong cell-mediated immunity and
anti-tumour effect. 
In view of these findings regarding RANTES’
effects on the immune response, we decided to
study the mechanism associated with tumour cell
growth following expression of RANTES in EG7 cells.
Thus we transfected EG7 cells with RANTES gene
and established an EG7 cell clone stably expressing
RANTES (500 pg/ml every 106 cells). We hypothe  -
sized that intra-tumoural higher level of RANTES
induced local accumulation of T cells and NK cells
in the tumour site, which can be activated
subsequently by EG7 cells to overcome the
occurrence of a hyporesponsive state, and elicited
a potent anti-tumour effect.
C57BL/6 mice were inoculated subcutaneously
(s.c.) with EG7 cells transfected with RANTES as
a model and then we observed the tumourigenicity
of EG7/RANTES and investigated the underlying
mechanism. Our data illustrated that RANTES gene
transfer elicited a significant anti-tumour effect
through more efficient induction of a specific and
non-specific anti-tumour immune response.
Material and methods
Animals
Female C57BL/6 mice (H-2Kb) aged 6-8 weeks
were purchased from Joint Ventures Sipper BK
Experimental Animal Company (Shanghai, China)
and housed in a specific pathogen-free condition
for all experiments.
Cell lines
EG7 cell line is derived from the murine T-cell
lymphoma EL-4 transfected with cDNA for
ovalbumin (OVA) and lack of B7-1 expression. The
expression vector pKGE839 encoding RANTES was
transfected into EG7 cells by using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) to establish
an EG7 cell clone which stably expresses RANTES
as described above by us (500 pg/ml every 106
cells) (a gift generously provided by Ms. Huiling Diao
from Binzhou Medical College). YAC-1, an NK-
sensitive lymphoma cell line of A/S (H-2a) origin,
and EL4, a T-lymphoma cell line of C57BL/6 origin
were obtained from American Type Culture
Collection (ATCC, Manassas, VT, USA), maintained
in RPMI-1640 medium supplemented with penicillin
100 U/ml, streptomycin 100 μg/ml, 2-merca  -
ptoethanol 50 mmol/l, and 10% fetal calf serum.
EG7 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal calf serum (FCS,
Hyclone, Logan, UT, USA), penicillin (100 U/ml),
streptomycin (100 mg/ml), and G418 (500 μg/ml),
50 μg/ml gentamicin, and 2 mM glutamine. All
culture media were purchased from Gibco-BRL
(Gaithersburg, Md., USA), and fetal calf serum was
provided by Shanghai Institute of Biological
Products (Shanghai, China).
Reagents
The expressing vector pKGE839 containing
RANTES cDNA and the neomycin resistance gene
was also a gift from Active Biotech Research.
Recombinant murine interleukin (IL-2) was
purchased from Pharmingen (San Diego, CA, USA).
IL-2 and interferon-γ (IFN-γ) ELISA kits were
purchased from R&D System Incorporation
(Minneapolis, MN, USA). G418 was purchased from
CalBiochem (Merck, Darmstadt, Germany). Cytotox
96® Non-radioactive Cytotoxicity Assay kit was
purchased from Promega (Madison, WI, USA). Trizol
Reagent was purchased from Bio Basic
Incorporation. RevertAidTM First Strand cDNA
Synthesis Kit #K1622 was purchased from
Fermentas (Vilnius, Lithuania). Gene RulerTM 100
bp DNA ladder #SM0241 was purchased from
Fermentas (Lot:00014461). Blend TaqE was
purchased from Takara Incorporation (Osaka,
Japan). dNTPs 10 mM was purchased from Takara
Biotechnology Incorporation (Dalian). The primer
for VEGF and MMP-2 was synthesized by Shanghai
Biotechnology Company. 
Tumourigenicity of EG7 after RANTES gene
transfer
C57BL/6 mice were divided into two groups and
were s.c. injected into the hind limb with a dose
of 5 × 105 EG7 cells or EG7/RANTES cells,
respectively. The length and width of the tumour
mass were measured with calipers every other day
after tumour inoculation. Tumour size wasArch Med Sci 6, December / 2010 831
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expressed as 1/2 (length + width). Three mice of
each group were killed by cervical dislocation three
weeks after the tumour inoculation and the
tumour in the lateral hind leg was extracted and
weighed. An incision was made on the skin of the
abdomen using scissors, the entire peritoneal
cavity was opened, and finally the spleen was
taken out using forceps. Splenocytes isolated from
the mice were used for cytotoxic assay of NK cells
and CTL and cytokine induction as follows. Seven
mice in each group were observed for their
survival period. All experiments were performed
three times using individual groups of ten mice.
Data are representative of three experiments
performed. All animal experimental procedures
were approved by the Animal Care Committee of
Binzhou Medical College Graduate School of
Medicine.
Cytotoxic assay of NK cells and CTL
Splenic lymphocytes were isolated from the
sacrificed mice three weeks after the tumour
inoculation. The erythrocytes were depleted with
0.83% ammonium chloride and macrophages
were removed by adherence of splenocytes on
plastic plates for 2 h. The non-adherent
lymphocytes were directly used as NK cells. The
lymphocytes were co-cultured with inactivated
EG7 cells, EG7/RANTES cells (treated with
50 μg/ml mitomycin for 30 min) for 7 days in the
presence of 20 U/ml murine recombinant IL-2
(San Diego, CA, USA) and then collected as CTL.
The NK cell activity and CTL activity were
determined by lactate dehydrogenase (LDH)
release assay with CytoTox 96® Non-Radioactive
Cytotoxicity Assay kit (Promega, Madison, WI,
USA) [28]. The target cells (YAC-1 cells, EG7 cells
or EG7/RANTES) were washed three times with
RPMI 1640 medium containing 5% FCS to remove
adherent LDH derived from lysed cells. The cell
suspension was diluted with RPMI 1640 medium
containing 5% FCS to the final concentration of 
1 × 105 cells/ml. 100 μl of target cell suspension
and 100 μl of different ratios of effector cells were
pipetted together into the wells of a round-
bottomed microtitre plate. Suspensions
containing exclusively effector cells, target cells,
or culture medium, respectively, served as
controls to estimate the LDH background. The
plates were incubated for 4 h in a humidified 5%
CO2 atmosphere at 37°C. After incubation, they
were centrifuged for 10 min. Then 100 μl of the
supernatant from each well was transferred to
the corresponding well of the enzymatic assay
plate. 50 μl of reconstituted substrate mix
(containing lactate and NAD+) was added to each
well. The plate was covered and incubated at
room temperature (protected from light). Thirty
minutes later, 50 μl of stop solution was added
to each well. The reaction was measured in an
ELISA reader at a wavelength of 490 nm.
Calculations were carried out according to the
following formula: % of specific lysis = 100 ×
(experimental – effector spontaneous – target
spontaneous)/(target maximum – target spon  -
taneous).
Cytokine induction and measurement of
splenocytes
The non-adherent splenocytes were derived from
mice three weeks after the tumour inoculation and
the cells were washed three times with PBS. For
induction of cytokines, 5 × 106 cells of splenocytes
were incubated with inactivated EG7 cells,
EG7/RANTES (treated with 50 μg/ml mitomycin for
30 min) at a 10 : 1 ratio in a total volume of 1 ml at
37°C, 5% CO2 for 72 h. Culture supernatants were
harvested at 24 h (for IL-2 assay) or 72 h (for IFN-γ
assay) and stored at –20°C for measurement of
cytokines using a standard sandwich ELISA
technique with corresponding kits purchased from
R&D System Incorporation (Minneapolis, MN, USA).
Determination of intratumoural VEGF and
MMP-2 mRNA level by semi-quantitative PCR
Subcutaneous tumour nodules were extracted
from sacrificed tumour-bearing mice three weeks
after the tumour inoculation. Total RNA was
extracted from subcutaneous tumour tissues by
Trizol Reagent (Bio Basic Inc. Canada), according to
the instructions of the manufacturer. For each
sample, 1 μg of RNA was reverse-transcribed using
a RevertAidTM First Strand cDNA Synthesis Kit
#K1622 (Fermentas, Vilnius, Lithuania) in a total
volume of 20 μl. cDNA as read-out of the mRNA was
quantitated in a competitive PCR using specific
primers for VEGF and MMP-2. Primers for
amplification of VEGF were 5’-CTG CTC TCT TGG
GTG CAC TGG-3’ (sense) and 5’-CAC CGC CTT GGC
TTG TCA CAT-3’ (antisense), with an expected PCR
product of VEGF (431 bp). Primers for amplification
of MMP-2 were 5’-CAC CAT CGC CCA TCA TCA AGT-
3’ (sense) and 5’-’TGG ATT CGA GAA AAG CGC AGC
GG-3’ (antisense), with an expected PCR product of
399 bp. Primers for amplification of β-actin were 5’-
TGG AAT CCT GTG GCA TCC ATG AAA C-3’ (sense)
and 5’-TAA AAC GCA GCT CAG TAA CAG TCC G-3’
(antisense), with an expected PCR product of
348 bp.
PCR products of VEGF, MMP-2 and β-actin were
visualized by electrophoresis in  2.5% agarose gel
containing 0.5 μg/ml ethidium bromide. The
amplified VEGF, MMP-2 and β-actin were
photographed using the Kodak EDAS120 digital
imaging system version 3 (Gibco-BRL). 832 Arch Med Sci 6, December / 2010
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Histological examination 
Subcutaneous tumour nodules were extracted
from three sacrificed tumour-bearing mice three
weeks after the tumour inoculation. The tumour
sample was fixed in 10% formalin solution,
dehydrated and embedded in paraffin. Thin-sliced
sections were stained with haematoxylin and eosin.
Finally two slices were prepared from each sacrificed
mouse and in total six tissue slices were used to
observe necrosis in the tumour tissue for each
group. For the evaluation of tumour necrosis, we
assigned the following: – no necrosis; + less than
one-third of the tumour size; ++ between one-third
and two-thirds of the tumour size; +++ more than
two-thirds of the tumour size.
Statistical analysis
All the experiments were run in triplicate and the
results are means ± SD of triplicate determinations
(or representative data from one or two
independent experiments). Statistical analysis was
performed using Student’s t test and log-rank test
(for survival analysis). The difference was
considered statistically significant when the P value
was less than 0.05.
Results
RANTES reduced the tumourigenicity of EG7
cells
The gene encoding RANTES was transduced
into EG7 cells. Normal C57BL/6 mice were
inoculated s.c. with a dose of 5 × 105 EG7 or
EG7/RANTES cells, respectively. The results in
Figure 1A showed that the tumourigenicity of EG7
cells after RANTES gene transfer was markedly
reduced compared with that of EG7 cells 
(P < 0.05). The tumour-bearing mice were killed
three weeks after the tumour inoculation and the
tumour in the lateral rear leg was extracted and
weighed. The results in Figure 1B illustrated that
the tumour weight was also less from
EG7/RANTES tumour-bearing mice than that of
EG7 tumour-bearing mice (P < 0.05). Seven
tumour-bearing mice in each group were
observed for their survival period. The results in
Figure 1C showed that EG7/RANTES tumour-
bearing mice survived much longer than EG7
tumour-bearing mice (P < 0.05). Of seven mice
inoculated with EG7/RANTES, two were tumour-
free and survived more than 90 days. These data
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Figure 1. Reduced tumourigenesis of EG7 after
RANTES gene transfer. EG7 cells or EG7/RANTES
cells were s.c. injected into C57BL/6 mice at a dose
of 5 × 105 cells. Ten tumour-bearing mice in each
group were analysed. The length and width of the
tumour mass were measured with calipers every
other day. Tumour-bearing mice in each group were
observed for their survival time during 90 days. (A)
Inhibition of tumour growth after RANTES gene
transfer. (B) Tumour weight extracted from tumour-
bearing mice. (C) Survival period of tumour-bearing
mice. An asterisk indicates a statistically significant
difference (P < 0.05)
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EG7               EG7/RANTESsuggested that RANTES gene transfer elicited a more
potent and specific anti-tumour effect in vivo.
Increased NK cell activity by RANTES
Three weeks after the tumour inoculation, the
splenocytes isolated from sacrificed tumour-
bearing mice of each group were used in
a cytolytic assay against YAC-1 cells at effec  tor:
target (E:T) ratios of 25 : 1, 50 : 1 and 100 : 1
by lactate dehydrogenase (LDH) release assay. As
shown in Figure 2, NK cell activity of EG7/RANTES
tumour-bearing mice increased when compared
with that of EG7 tumour-bearing mice (P < 0.05).
It suggested that the enhanced non-specific
immunity might also be involved in the anti-
tumour response of RANTES.
More potent CTL cytotoxicity induced by
RANTES 
The splenocytes derived from tumour-bearing
mice of each group were re-stimulated in vitro with
inactivated EG7 or EG7/RANTES cells for seven days
in the presence of murine recombinant IL-2 
(20 U/ml) and then collected as CTL effector cells.
EG7 and EG7/RANTES cells were used as target
cells, respectively. The CTL activity was determined
at effector:target ratios of 25 : 1, 50 : 1 and 100 : 1
by lactate dehydrogenase (LDH) release assay.
Consistent with the protection against the challenge
of T lymphoma cells, EG7/RANTES tumour-bearing
mice exhibited a T lymphoma-specific CTL response,
which was higher than that of EG7 tumour-bearing
mice (P < 0.05) (Figure 3). 
Enhanced Th1 type cytokine production after
RANTES gene transfer   
Three weeks after the tumour inoculation, we
determined the production of IL-2 (for 24 h) and
IFN-γ (for 72 h) by splenocytes stimulated in vitro
with inactivated EG7 or EG7/RANTES cells at a 10:1
ratio in a total volume of 1 ml at 37°C, 5% CO2. The
data in Figure 4 show that splenocytes from
EG7/RANTES tumour-bearing mice secreted higher
levels of IL-2 and IFN-γ when compared with those
from EG7 tumour-bearing mice (P < 0.05). 
Reduced expression of VEGF and MMP-2 after
RANTES gene transfer 
Three weeks after the tumour inoculation,
VEGF and MMP-2 mRNA expression was analysed
by semi-quantitative polymerase chain reaction
(PCR). As shown in Figure 5, it was markedly
observed in the tumour tissue from EG7 tumour-
bearing mice. The intratumoural expression of
VEGF and MMP-2 mRNA from EG7/RANTES
tumour-bearing mice was significantly less than
that of EG7 tumour-bearing mice. This indicated
that RANTES gene could efficiently inhibit
angiogenesis in the tumour tissue. 
Manifest necrosis in the tumour tissue after
RANTES gene transfer
Subcutaneous tumour nodules were extracted
from tumour-bearing mice that were killed three
Arch Med Sci 6, December / 2010 833
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Figure 2. Induction of higher NK activity by RANTES.
Normal C57BL/6 mice were s.c. inoculated with
a dose of 5 × 105 EG7 cells or EG7/RANTES cells.
Three mice in each group were killed three weeks
after the tumour inoculation, and their splenocytes
were isolated and used in cytolytic assays against
YAC-1 cells. An asterisk indicates a statistically
signi?cant difference (P < 0.05)
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Figure 3. Induction of higher CTL activity against
target cells by RANTES. Normal C57BL/6 mice were
s.c. inoculated with a dose of 5 × 105 EG7 cells or
EG7/RANTES cells. Three mice in each group were
killed three weeks after the tumour inoculation, and
their splenocytes were re-stimulated in vitro for
seven days with inactivated EG7 cells or EG7/RANTES
cells in the presence of murine recombinant IL-2 
(20 U/ml) and assayed for their cytotoxicity against
EG7 cells or EG7/RANTES cells, respectively. Data are
representative of three independent experiments.
An asterisk indicates a statistically significant
difference (P < 0.05)834 Arch Med Sci 6, December / 2010
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weeks after tumour challenge. Histological
examination of the tumour mass showed that the
most obvious tumour necrosis was present inside
the tumour from EG7/RANTES tumour-bearing
mice. However, little necrosis was found inside the
tumour from EG7 tumour-bearing mice (Table I).
Discussion 
Cytokine gene transfer to cancer cells has been
recently developed as an attractive mechanism of
drug delivery in situ without the toxic effects
associated with systemic administration. However,
the anti-tumour effects of a cancer cell line
genetically modified with cytokine gene alone are
still far from satisfactory. The reason may be
partially due to the failure to recruit lymphocytes
of the appropriate specificity. Many studies have
demonstrated that chemokine gene transfer elicits
potent anti-tumour activity. 
CCL5 is chemotactic for T cells, eosinophils, and
basophils, and plays an active role in recruiting
leukocytes into inflammatory sites. With the help
of particular cytokines (IL-2 and IFN-γ) that are
released by T cells, CCL5 also induces the
proliferation and activation of certain NK cells to
form CC-chemokine-activated killer (CHAK) cells [9]. 
Opportunities exist for manipulating chemokine
expression in the tumour microenvironment with
therapeutic intent. Transfection of tumour cells to
express several chemokines before implantation in
mice has shown improved tumour control in several
models [10]. In this study, we selected the EG7 cell
line (EL-4 transfected with ovalbumin gene). The
intra-tumoural higher levels of RANTES caused local
accumulation of more NK cells and T cells that can
subsequently be activated by EG7 cells, which will
contribute to inducing a more potent anti-tumour
effect. Our results shown in Figure 1C demonstrated
that RANTES gene transfer into EG7 cells could
inhibit its tumourigenicity and prolonged the
survival of tumour-bearing mice survival (2 of 
7 EG7/RANTES tumour-bearing mice were tumour-
free and survived more than 90 days). 
The mechanism involved in the potent anti-
tumour efficacy of RANTES might be related to the
following aspects. First, effective induction of a cell-
mediated immune response by RANTES might play
an important role. Some authors have suggested
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Figure 4. Higher levels of Th1 type cytokines induced
by RANTES. Production of IL-2 and IFN-γ by
lymphocytes derived from tumour-bearing mice.
Three mice in each group were killed three weeks
after tumour inoculation. 5 × 106 splenocytes were
incubated with inactivated EG7 cells or EG7/RANTES
cells at a 10 : 1 ratio in a total volume of 1 ml at 37°C,
5% CO2 atmosphere for 24 h and 72 h, and
supernatants were harvested for the detection 
of cytokines by ELISA. An asterisk indicates
a statistically significant difference (P < 0.05)
Figure 5. Intratumoural VEGF and MMP-2 mRNA
expression after RANTES gene transfer. Three weeks
after the tumour inoculation, total RNA was
extracted from subcutaneous tumour tissue by Trizol.
The intratumoural VEGF and MMP-2 mRNA
expression was analysed by semi-quantitative PCR.
PCR products were visualized by electrophoresis in
a 2.5% agarose gel containing 0.5 μg/ml ethidium
bromide. One of three independent experiments
with similar results is shown
VEGF
12
1 – EG7/RANTES, 2 – EG7
MMP-2
β-actin
Groups EG7 EG7/RANTES
Necrosis – ++
Table I. Pathological analysis of tumour mass from
tumour-bearing mice. Subcutaneous tumour nodules
were extracted from sacrificed tumour-bearing mice
three weeks after the tumour inoculation. The
tumour sample was used to prepare for paraffin
section and then thin-sliced sections were stained
with haematoxylin and eosin. The results represent
mean assessment of necrosis in tissue samples
Tumour necrosis: (–) no necrosis, (+) less than 1/3 of the tumour size, 
(++) between 1/3 and 2/3 of the tumour size, (+++) more than 2/3 of
the tumour sizeArch Med Sci 6, December / 2010 835
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that the anti-tumour activity of RANTES observed
in animal models might be mainly mediated by NK
cells and CTL [1, 3-6]. In our study, the splenic NK
and CTL cytotoxicities were markedly enhanced
after RANTES gene transfer. The results in Figure 2
showed that NK cell activity of EG7/RANTES
tumour-bearing mice (39.5%) was significantly
higher than that of EG7 tumour-bearing mice
(19.6%) (P < 0.05). Similarly, the results in Figure 3
showed that CTL activity of EG7/RANTES tumour-
bearing mice (49.5%) was significantly higher than
that of EG7 tumour-bearing mice (27.6%) (P < 0.05).
This suggested that the non-specific and specific
anti-tumour immunity were potently activated and
might be involved in the anti-tumour response of
RANTES. These results suggested that priming of
NK cells and CTL by RANTES induced effective anti-
tumour immunity. 
Secondly, RANTES inhibited angiogenesis in vivo.
Malignant tumours do not grow beyond 2-3 mm3
and cannot metastasize unless they stimulate the
formation of new blood vessels and thus provide
a route for the increased inflow of nutrients and
oxygen and outflow of waste products [11]. In our
study, the results in Figure 5 showed that
expression of VEGF and MMP-2 was reduced in
tumour tissues from EG7/RANTES tumour-bearing
mice. Moreover, the results of histological
examination in Table I also showed that manifest
necrosis was markedly observed to be present in
the tissue from EG7/RANTES tumour-bearing mice.
These results illustrated that RANTES inhibited
angiogenesis through inhibiting VEGF and MMP-2
expression, reducing new blood vessels and finally
causing manifest necrosis of tumour tissues due to
lack of nutrients.
Lastly, it is accepted that the balance between
Th1 and Th2 cells plays an important role in the
anti-tumour immune response [12]. IL-2 and IFN-γ,
produced by Th1 cells and NK cells, are critically
important for the induction of anti-tumour cellular
immunity in vivo [13]. Therefore, induction of Th1
type cytokines can be beneficial for tumour
eradication. In Figure 4, the results showed that the
production of IL-2 and IFN-γ from splenocytes
increased to 440 pg/ml and 1150 pg/ml after
RANTES gene transfer, respectively. This may be
related to the fact that more T cells and NK cells
were attracted by RANTES and activated by DCs
presenting tumour antigens. As a result, more Th1
type cytokines were produced by NK cells and
activated T cells. 
Several cell types within the tumour micro  -
environment could potentially produce the
chemokines important for recruitment of effector
CTL. Our analysis of T lymphoma indicates that
a subset of such lines is capable of producing an
expanded array of chemokines itself. However,
additional cell types may contribute to chemokine
synthesis within the complexity of the tumour
microenvironment in vivo. Macrophages, endothelial
cells and even recruited T cells could theoretically
secrete relevant chemokines and positively reinforce
recruitment of additional specific T-cell subsets [14].
Further work will be required to identify the cell
types producing each chemokine within the
metastatic melanoma microenvironment in
individual patients using in situ assays.
Other previous work has shown that granulocyte
macrophage colony-stimulating factor (GM-CSF),
macrophage inflammatory protein-1 (MIP-1), and
other  chemokines can recruit antigen-presenting
cells to the site of inoculation and increase vaccine-
elicited immune responses in mice [15-19]. The
present study extends these observations by
demonstrating that the specific chemotactic signal
of RANTES results in dramatic and synergistic
effects at the host level to resist tumour formation.
Ultimately, we hope that the study will provide
insights that lead to the development of more
effective vaccine-based cancer immunotherapy.
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